Valeant Pharmaceuticals Intl Inc (VRX) Tests Support After Papa Comments

Valeant Pharmaceutical Intl Inc (NYSE:VRX) shares are testing the $30 level after comments from CEO Joseph Papa

Sep 8, 2016 at 1:11 PM
facebook X logo linkedin


While several biotechs have had their day in the sun this week, sector peer Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is struggling yet again, after comments made to CNBC by CEO Joseph Papa. Papa last night said Valeant is looking to reduce some of its $30 billion in debt through the sales of non-core assets, and he would "never say never" to selling core assets like Bausch & Lomb. The CEO also said VRX has retained new general counsel to help the biotech navigate lawsuits and investigations into its pricing practices.

Although VRX is down by over 87% year-over-year, sentiment in the option pits has had a bullish lean as of late. VRX's 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 2.17, in the top 76th percentile of its annual range. In addition, VRX's Schaeffer's put/call open interest ratio (SOIR) of 0.80 sits lower than 87% of all other readings from the past 12 months, indicating short-term option players have rarely been more call-skewed over the past year.

Given VRX's recent struggles, though, some of the call-heavy action in the option pits could actually be short sellers hedging their bets. VRX's short interest is up 11.5% over the last two reporting periods.

On one hand a certain amount of optimism may not be unwarranted, considering VRX's recent breakout above its 30-day and 50-day moving averages. Also encouraging is VRX's move above the $28 level – specifically $28.09, which is 150% above the year-to-date closing low of $18.73, notched on June 27. The shares were rejected at the $28 mark in mid-August, but seem to have found support since surpassing and successfully testing the level on Sept. 2.

On the other hand, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is currently struggling to keep its footing above the $30 level. Although the shares have touched or traded above this round-number level every session since Aug. 17, VRX has only managed a weekly close above the $30 level once so far. The shares are hovering near this critical level today, most recently seen down 0.3% at $30.16.

VRX 090816

 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI